Clinical Trial Detail

NCT ID NCT04418167
Title JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors JS InnoPharm, LLC
Indications

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

Therapies

JSI-1187

Dabrafenib + JSI-1187

Age Groups: senior adult

Additional content available in CKB BOOST